After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking off 2025 with a return to the dealmaking table. Under a new licensing pact, ...
Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...
The biotech industry has certainly hit the ground running in 2026. In its first edition of the year, the biotech bi-weekly highlights new products that can visualize multimodal biological data at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results